The urgency behind the effort is easy to grasp. Intrahepatic cholangiocarcinoma accounts for roughly 8 to 15 percent of all primary malignant liver tumors, second only to hepatocellular carcinoma, and its incidence has been climbing. Five-year overall survival sits at approximately nine percent. Surgery remains the only curative option, yet 70 to 80 percent of patients arrive at the clinic with disease that is either locally unresectable or already metastatic. For them, systemic therapy can delay progression but typically extends survival to only about a year. Against that grim backdrop, the discovery that roughly 40 to 50 percent of these tumors carry actionable genetic alterations has transformed the conversation, turning molecular profiling from an academic exercise into a clinical necessity.

The guideline, developed under the auspices of the Chinese Anti-Cancer Association’s liver cancer and pathology societies with international co-authors from Singapore, Australia, the United States and China, was registered on a transparency platform for practice guidelines and graded its evidence using the GRADE system. Its central message is blunt: molecular testing is recommended for all patients with intrahepatic cholangiocarcinoma, and it is essential for those with unresectable or metastatic disease, because the tumor’s genetic landscape differs markedly from that of extrahepatic bile duct cancers and gallbladder cancers, and even different pathological subtypes of the tumor behave differently at the DNA level.

At the top of the target list sits FGFR2, a receptor tyrosine kinase gene that is rearranged or fused in between 6.6 and 20 percent of Chinese patients with the disease, particularly in the small-duct subtype. These fusions typically break the gene between exons 17 and 19, leaving the receptor’s kinase domain intact while deleting regulatory elements that normally switch the receptor off, resulting in constitutive growth signaling. More than 140 partner genes have been identified, with BICC1 the most frequent. Two drugs, pemigatinib and futibatinib, are now approved by regulators in the United States and China for previously treated patients whose tumors harbor FGFR2 fusions, and both are recommended as second-line options in major treatment guidelines.

Choosing the right detection method for FGFR2 turns out to matter enormously, and the consensus devotes unusual technical detail to the question. Fluorescence in situ hybridization with break-apart probes can flag rearrangements but cannot identify fusion partners and may miss closely spaced intrachromosomal events. DNA-based next-generation sequencing can simultaneously detect mutations, amplifications and fusions across many genes, but it cannot confirm that a detected fusion actually produces a functional RNA transcript. RNA-based sequencing, by contrast, provides direct evidence of functional fusions and can uncover novel partners, with concordance between the two sequencing approaches reaching 98 percent. The panel therefore recommends combining DNA- and RNA-based sequencing, reserving FISH as a fallback when sequencing is unavailable, and explicitly discourages FGFR2 immunohistochemistry, which shows poor agreement with molecular methods. In a striking practical touch, the guideline even borrows interpretation thresholds from ALK testing in lung cancer, since no standardized cutoff for FGFR2 break-apart positivity exists.

A second pillar of the guideline concerns IDH1, a metabolic enzyme whose mutations occur in 4.9 to 20 percent of Chinese patients, again concentrated in the small-duct subtype. The inhibitor ivosidenib received United States approval in 2021 for previously treated, IDH1-mutant cholangiocarcinoma, with a companion diagnostic test cleared alongside it. Mutations cluster at position 132, most commonly R132C, a detail with real diagnostic consequences: the commercial immunohistochemistry antibody targets the R132H variant common in gliomas and cannot recognize R132C, limiting staining’s usefulness here. Sequencing, preferably by next-generation platforms that can capture multiple loci, is the preferred route, and the panel notes that secondary resistance mutations such as D279N, or oncogenic IDH2 mutations like R172K, can emerge under treatment pressure, making comprehensive sequencing valuable even after therapy begins.

The guideline then marches through a roster of additional targets. BRAF V600E, present in a subset of the 4.2 percent of Chinese patients with BRAF mutations, is sensitive to the approved dabrafenib-plus-trametinib combination, while non-V600 variants respond to MEK inhibitors but not BRAF inhibitors, so the panel urges attention beyond the flagship site. HER2 overexpression and ERBB2 amplification, found in 1.8 to 8 percent of patients, open doors to trastuzumab-based regimens including trastuzumab deruxtecan, with immunohistochemistry prioritized and equivocal cases confirmed by FISH or sequencing, interpreted for now by adapting breast and gastric cancer criteria. Rarer but druggable alterations receive their due as well: NTRK fusions in under one percent of patients, RET fusions in 1.8 percent, KRAS mutations in 12.4 to 25 percent, and NRG1 fusions in roughly two percent, each with preferred platforms, mostly RNA-based sequencing for fusions and broad DNA panels for point mutations.

Immune checkpoint eligibility also earns a formal recommendation. Deficient mismatch repair or high microsatellite instability, present in 1.6 to 6 percent of Chinese patients, predicts response to immunotherapy, and several checkpoint inhibitors are approved for such tumors in both the United States and China. The panel endorses mismatch repair immunohistochemistry or polymerase chain reaction-based microsatellite testing as primary methods, and adds a cautionary note drawn from a study of 1,942 solid tumors: sequencing-based microsatellite calls are fully concordant with conventional methods only at the extremes, so borderline results must be validated by immunohistochemistry or PCR before treatment decisions rest on them.

Equally pragmatic are the recommendations about samples themselves. Because intrahepatic cholangiocarcinoma is stroma-rich, tumor cell content in biopsies is often low; in one series of 123 advanced biliary tract cancers, more than a quarter of samples were unsuitable for sequencing due to insufficient tumor content. The consensus requires pathologists to verify at least 20 percent tumor cellularity and a minimum of 50 tumor cells before testing, and urges clinicians to obtain enough tissue in a single procedure for both diagnosis and molecular workup. Tissue remains the gold standard, with cytology cell blocks as the fallback and liquid biopsy of circulating tumor DNA as a last resort at accredited laboratories, since concordance between blood and tissue varies dramatically, from 87 to 100 percent for point mutations down to just 18 percent for FGFR2 fusions. Primary lesions are preferred for initial testing, though metastatic sites may be sampled when the primary is inaccessible, and repeat biopsy after progression on targeted therapy is explicitly encouraged to map resistance mechanisms.

The panel closes by sorting biomarkers into essential and optional categories, the latter including emerging targets such as PTEN loss, Claudin 18.2 expression and BRCA1/2 mutations that may guide trial enrollment, and it commits to periodic revisions as new drugs and data accumulate. For a cancer with a nine percent five-year survival rate, the stakes of getting testing right could hardly be higher. What this guideline offers is a shared playbook: a single, evidence-graded document telling laboratories and clinicians worldwide which genes to interrogate, which platforms to trust, how to interpret ambiguous signals, and when to re-biopsy, so that every patient with this aggressive tumor has the best possible chance of finding a therapy matched to the specific molecular engine driving their disease.

Subject of Research: Precision molecular biomarker testing guidelines for intrahepatic cholangiocarcinoma

Article Title: Guideline of precisional testing in intrahepatic cholangiocarcinoma: an international expert consensus

Article References: Zhang, X., Han, J., Shi, R., Yu, B., Zhang, X., Li, B., Sheng, X., Li, Z., Zou, Y., Sun, H., Shi, G., Wang, H. L., Zhou, J., Fan, J., Cong, W., & Ji, Y. (2025). Guideline of precisional testing in intrahepatic cholangiocarcinoma: an international expert consensus. Clinical Cancer Bulletin, 4(1), Article 9. https://doi.org/10.1007/s44272-025-00036-0

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00036-0

Keywords: intrahepatic cholangiocarcinoma, molecular testing, FGFR2 fusions, IDH1 mutations, next-generation sequencing, targeted therapy, biomarkers, precision oncology, bile duct cancer, HER2, microsatellite instability, expert consensus